Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

Trial Profile

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2019

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms DETERMINE
  • Sponsors MedImmune
  • Most Recent Events

    • 18 Mar 2019 Planned End Date changed from 2 Apr 2019 to 31 Dec 2019.
    • 16 Nov 2017 Planned End Date changed from 2 Apr 2018 to 2 Apr 2019.
    • 15 Aug 2017 Planned End Date changed from 1 Apr 2017 to 2 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top